دورية أكاديمية
أعرض في EDS

Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.

التفاصيل البيبلوغرافية
العنوان: Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
المؤلفون: Chida T; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. tchida@hama-med.ac.jp.; Department of Regional Medical Care Support, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. tchida@hama-med.ac.jp., Ohta K; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan., Noritake H; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan., Matsushita M; Department of Gastroenterology, Shimada General Medical Center, 1200-5 Noda, Shimada, Shizuoka, 427-8502, Japan., Murohisa G; Department of Hepatology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Hamamatsu, Shizuoka, 430-8558, Japan., Kageyama F; Department of Hepatology, Hamamatsu Medical Center, 328 Tomitsuka-Cho, Hamamatsu, Shizuoka, 432-8580, Japan., Sasada Y; Department of Hepatology, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, 438-8550, Japan., Oyaizu T; Department of Gastroenterology, Shizuoka City Shizuoka Hospital, 10-93 Otemachi, Shizuoka, Shizuoka, 420-8630, Japan., Tsugiki M; Minoru Medical Clinic, 1784-1 Mishima-Cho, Hamamatsu, Shizuoka, 430-0853, Japan., Tamakoshi K; Tamakoshi Clinic, 262-1 Maruzuka-Cho, Hamamatsu, Shizuoka, 435-0046, Japan., Nakajima T; Elm Medical Clinic, 5-17-22 Handayama, Hamamatsu, Shizuoka, 431-3125, Japan., Suda T; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan., Kawata K; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
المصدر: Scientific reports [Sci Rep] 2024 May 13; Vol. 14 (1), pp. 10864. Date of Electronic Publication: 2024 May 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Amino Acid Oxidoreductases*/blood , Carcinoma, Hepatocellular*/blood , Carcinoma, Hepatocellular*/virology , Hepatitis C, Chronic*/complications , Hepatitis C, Chronic*/drug therapy , Hepatitis C, Chronic*/blood , Hepatitis C, Chronic*/virology , Liver Neoplasms*/blood , Liver Neoplasms*/virology , Sustained Virologic Response*, Female ; Humans ; Male ; alpha-Fetoproteins/metabolism ; alpha-Fetoproteins/analysis ; Antiviral Agents/therapeutic use ; Biomarkers, Tumor/blood ; Hepacivirus ; Retrospective Studies
مستخلص: Lysyl oxidase-like 2 (LOXL2) mediates the crosslinking of extracellular collagen, reflecting qualitative changes in liver fibrosis. This study aimed to validate the utility of serum LOXL2 levels as a predictive biomarker for the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection who achieved a sustained virological response (SVR). This retrospective study included 137 patients with chronic HCV infection without history of HCC development and who achieved SVR via direct-acting antiviral therapy. Median LOXL2 levels decreased significantly after SVR achievement (pre-Tx, 2.33 ng/mL; post-Tx, 1.31 ng/mL, p < 0.001). Post-Tx LOXL2 levels, fibrosis-4 index, platelet counts, Wisteria floribunda agglutinin-positive human Mac-2 binding protein levels, and alpha-fetoprotein (AFP) levels were identified as independent predictive factors for post-SVR HCC development in the univariate analysis. The incidence of post-SVR HCC development was significantly higher in patients with post-Tx LOXL2 levels ≥ 2.08 ng/mL and AFP levels ≥ 5.0 ng/mL than in patients with elevated levels of either marker or with lower marker levels. Serum LOXL2 levels can serve as a predictive biomarker for HCC development after achieving SVR. The combination of serum LOXL2 and AFP levels provides robust risk stratification for HCC development after SVR, suggesting an enhanced surveillance strategy.
(© 2024. The Author(s).)
References: N Engl J Med. 2001 Feb 15;344(7):495-500. (PMID: 11172192)
Gastroenterology. 2017 Oct;153(4):996-1005.e1. (PMID: 28642197)
J Hepatol. 2021 May;74(5):1053-1063. (PMID: 33242501)
Dig Liver Dis. 2019 Feb;51(2):310-317. (PMID: 30473220)
Hepatology. 2022 Jul;76(1):139-154. (PMID: 35030279)
Biochemistry. 1970 Nov 10;9(23):4486-92. (PMID: 5474144)
J Hepatol. 2020 Sep;73(3):540-548. (PMID: 32243960)
Mol Clin Oncol. 2021 Oct;15(4):215. (PMID: 34476099)
Cancers (Basel). 2022 Feb 06;14(3):. (PMID: 35159094)
Cancer Med. 2023 May;12(9):10175-10186. (PMID: 37078924)
J Biol Chem. 2013 Oct 18;288(42):30000-30008. (PMID: 24014025)
J Hepatol. 2013 Oct;59(4):675-83. (PMID: 23712051)
Proc Natl Acad Sci U S A. 1968 Oct;61(2):708-16. (PMID: 5246001)
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1840-1849.e16. (PMID: 30580095)
Hepatol Res. 2022 Oct;52(10):824-832. (PMID: 35749289)
Sci Rep. 2023 Jun 2;13(1):8992. (PMID: 37268672)
Int J Mol Sci. 2022 Jun 02;23(11):. (PMID: 35682926)
Int J Mol Sci. 2023 Jul 21;24(14):. (PMID: 37511503)
Blood. 2011 Oct 6;118(14):3979-89. (PMID: 21835952)
J Hepatol. 2017 Dec;67(6):1204-1212. (PMID: 28802876)
Hepatology. 2012 Aug;56(2):532-43. (PMID: 22271347)
Hepatology. 2014 Nov;60(5):1645-58. (PMID: 25048396)
Biol Open. 2014 Feb 15;3(2):129-37. (PMID: 24414204)
Hepatol Res. 2018 Dec;48(13):1131-1139. (PMID: 30030872)
JAMA. 2020 Mar 02;:. (PMID: 32119034)
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1044-1055.e3. (PMID: 26804385)
Aliment Pharmacol Ther. 2023 May;57(10):1056-1065. (PMID: 37038283)
Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95. (PMID: 24321207)
Liver Cancer. 2019 Mar;8(2):121-129. (PMID: 31019902)
Gastroenterology. 2018 Oct;155(4):1140-1153. (PMID: 29990488)
World J Gastroenterol. 2021 Oct 28;27(40):6737-6749. (PMID: 34790004)
Hepatology. 2007 Jul;46(1):32-6. (PMID: 17567829)
Int J Mol Sci. 2023 Sep 21;24(18):. (PMID: 37762708)
Eur J Pharmacol. 2021 Feb 5;892:173754. (PMID: 33248114)
J Hepatol. 2017 Sep 05;:. (PMID: 28887168)
J Hepatol. 2022 Apr;76(4):812-821. (PMID: 34871626)
Hepatol Res. 2017 Sep;47(10):1021-1031. (PMID: 27859993)
JGH Open. 2021 Sep 21;5(10):1203-1209. (PMID: 34622009)
J Clin Oncol. 2015 Feb 20;33(6):550-8. (PMID: 25512453)
Liver Int. 2021 Feb;41(2):276-287. (PMID: 32998174)
Hepatol Int. 2020 Dec;14(6):1023-1033. (PMID: 33277685)
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188435. (PMID: 32976981)
Liver Cancer. 2017 Nov;6(4):325-336. (PMID: 29234636)
Front Immunol. 2020 Mar 31;11:480. (PMID: 32296422)
JAMA Netw Open. 2020 Sep 1;3(9):e2015626. (PMID: 32870314)
Mol Clin Oncol. 2023 Aug 24;19(4):80. (PMID: 37719044)
Curr Opin Gastroenterol. 2019 May;35(3):137-144. (PMID: 30865043)
J Hepatol. 2023 Feb;78(2):281-292. (PMID: 36208843)
Eur J Gastroenterol Hepatol. 2023 Feb 1;35(2):219-226. (PMID: 36574313)
Int J Mol Sci. 2016 Dec 20;17(12):. (PMID: 27999409)
Dig Dis Sci. 2023 May;68(5):2115-2122. (PMID: 36526814)
J Clin Microbiol. 2019 Jan 2;57(1):. (PMID: 30381417)
Am J Manag Care. 2023 Oct 1;29(10):e299-e306. (PMID: 37870551)
Medicina (Kaunas). 2023 Aug 08;59(8):. (PMID: 37629725)
Panminerva Med. 2018 Dec;60(4):185-191. (PMID: 29856183)
Dig Liver Dis. 2023 Jul;55(7):907-917. (PMID: 36775720)
J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. (PMID: 32346535)
Clin Infect Dis. 2016 Sep 15;63(6):723-9. (PMID: 27282709)
J Viral Hepat. 2023 Jun;30(6):559-566. (PMID: 36890735)
Int J Mol Sci. 2019 Apr 02;20(7):. (PMID: 30986934)
Hepatol Commun. 2022 Nov;6(11):3194-3211. (PMID: 35894804)
Hepatology. 2020 Aug;72(2):729-741. (PMID: 32176358)
فهرسة مساهمة: Keywords: Alpha-fetoprotein (AFP); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Lysyl oxidase-like 2 (LOXL2); Sustained virological response (SVR)
المشرفين على المادة: 0 (alpha-Fetoproteins)
EC 1.4.- (Amino Acid Oxidoreductases)
0 (Antiviral Agents)
0 (Biomarkers, Tumor)
EC 1.4.3.- (LOXL2 protein, human)
تواريخ الأحداث: Date Created: 20240513 Date Completed: 20240513 Latest Revision: 20240711
رمز التحديث: 20240711
مُعرف محوري في PubMed: PMC11091085
DOI: 10.1038/s41598-024-61366-y
PMID: 38740815
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-61366-y